Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK01 in Moderate Alzheimer's Disease
NCT06189963Phase 2Recruiting
- Sponsor
- NKGen Biotech
- Start
- Nov 2023
- Primary completion
- Mar 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 2
01
Overview
A Phase 2 trial of troculeucel in Alzheimer's disease (AD), sponsored by NKGen Biotech. Started Nov 2023; status: recruiting.
02
Drugs
troculeucel
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06189963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189963.